Drug · CHEMBL848

LENALIDOMIDE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. LENALIDOMIDE. Drugs and targets, record CHEMBL848. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL848

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: LENALIDOMIDE; ChEMBL
ChEMBL ID: CHEMBL848; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Lenalidomide accord, Lenalidomide mylan, Revlimid; ChEMBL
Other names: CC-5013, CDC-501, Lenalidomida, NSC-747972, SYP-1512; ChEMBL
Other form: LENALIDOMIDE HYDROCHLORIDE MONOHYDRATE, CHEMBL6068337; Drugs and targets
DrugBank: DB00480; DrugBank
InChIKey: GOTYRUGSSMKFNF-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 6 of its 133 diseases, from ATC, DailyMed, EMA Human Drugs and TTD; Open Targets

Targets8

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
CRBN	CRL4(CRBN) E3 ubiquitin ligase	CRL4(CRBN) E3 ubiquitin ligase inhibitor	INHIBITOR	https://conductscience.org/library/genes/51185
CRBN	CRL4(CRBN) E3 ubiquitin ligase	CRL4(CRBN) E3 ubiquitin ligase modulator	MODULATOR	https://conductscience.org/library/genes/51185
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	CRL4(CRBN) E3 ubiquitin ligase inhibitor	INHIBITOR	https://conductscience.org/library/genes/8451
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	CRL4(CRBN) E3 ubiquitin ligase modulator	MODULATOR	https://conductscience.org/library/genes/8451
DDB1	CRL4(CRBN) E3 ubiquitin ligase	CRL4(CRBN) E3 ubiquitin ligase inhibitor	INHIBITOR	https://conductscience.org/library/genes/1642
DDB1	CRL4(CRBN) E3 ubiquitin ligase	CRL4(CRBN) E3 ubiquitin ligase modulator	MODULATOR	https://conductscience.org/library/genes/1642
RBX1	CRL4(CRBN) E3 ubiquitin ligase	CRL4(CRBN) E3 ubiquitin ligase inhibitor	INHIBITOR	https://conductscience.org/library/genes/9978
RBX1	CRL4(CRBN) E3 ubiquitin ligase	CRL4(CRBN) E3 ubiquitin ligase modulator	MODULATOR	https://conductscience.org/library/genes/9978

Source ChEMBL

Diseases133

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
plasma cell myeloma	Approval	DailyMed, EMA Human Drugs and TTD	478	470	https://conductscience.org/library/drugs?q=MONDO_0009693
diffuse large B-cell lymphoma	Phase 3	ClinicalTrials.gov	104	104	https://conductscience.org/library/drugs?q=MONDO_0018905
B-cell chronic lymphocytic leukemia	Phase 3	ClinicalTrials.gov	79	79	https://conductscience.org/library/drugs?q=MONDO_0004948
follicular lymphoma	Approval	EMA Human Drugs	67	64	https://conductscience.org/library/drugs?q=MONDO_0018906
myelodysplastic syndrome	Approval	DailyMed and EMA Human Drugs	64	59	https://conductscience.org/library/drugs?q=MONDO_0018881
non-Hodgkin lymphoma	Phase 3	ClinicalTrials.gov	48	48	https://conductscience.org/library/drugs?q=MONDO_0018908
mantle cell lymphoma	Approval	DailyMed and EMA Human Drugs	46	43	https://conductscience.org/library/drugs?q=MONDO_0018876
acute myeloid leukemia	Phase 3	ClinicalTrials.gov	36	36	https://conductscience.org/library/drugs?q=MONDO_0018874
marginal zone lymphoma	Phase 3	ClinicalTrials.gov	22	22	https://conductscience.org/library/drugs?q=MONDO_0017604
primary central nervous system lymphoma	Phase 2	ClinicalTrials.gov	20	20	https://conductscience.org/library/drugs?q=MONDO_0002571

1 to 10 of 133Source Open Targets

See all 133 diseases

Trials1,117

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00179647	Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma	Phase 3	1,913	2010-03-03	lenalidomide	Its name	ClinicalTrials.gov
NCT00689936	Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma	Phase 3	1,623	2017-08-11	lenalidomide	Its name	ClinicalTrials.gov
NCT00988208	Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer	Phase 3	1,059	2013-09-05	lenalidomide	Its name	ClinicalTrials.gov
NCT01476787	Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma	Phase 3	1,030	2025-05-14	lenalidomide	Its name	ClinicalTrials.gov
NCT01080391	Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma	Phase 3	792	2015-07-08	lenalidomide	Its name	ClinicalTrials.gov
NCT01109004	Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)	Phase 3	758	2018-06-11	lenalidomide	Its name	ClinicalTrials.gov
NCT01335399	Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma	Phase 3	748	2020-10-22	lenalidomide	Its name	ClinicalTrials.gov
NCT02252172	Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma	Phase 3	737	2020-01-09	lenalidomide	Its name	ClinicalTrials.gov
NCT01208662	Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65	Phase 3	729	2023-12-18	lenalidomide	Its name	ClinicalTrials.gov
NCT03710603	Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma	Phase 3	709	2024-12-24	lenalidomide	Its name	ClinicalTrials.gov

1 to 10 of 1,117

See all 1,117 trials

Comparisons in its trials202

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Docetaxel/Prednisone/Lenalidomide (DPL) vs Docetaxel/ Prednisone/and Placebo (DP): serious adverse events	283 of 525	176 of 521	1,046	NCT00988208	Trial comparisons
Lenalidomide and Dexamethasone (Rd) vs Carfilzomib, Lenalidomide, and Dexamethasone (CRd): serious adverse events	221 of 389	256 of 392	781	NCT01080391	Trial comparisons
E-Ld Cohort vs Ld Cohort: deaths from any cause	240 of 374	232 of 374	748	NCT01335399	Trial comparisons
E-Ld Cohort vs Ld Cohort: serious adverse events	293 of 371	279 of 371	742	NCT01335399	Trial comparisons
Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd): deaths from any cause	259 of 369	287 of 368	737	NCT02252172	Trial comparisons
Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd): serious adverse events	262 of 365	289 of 364	729	NCT02252172	Trial comparisons
Velcade Lenalidomide Dexamethasone (VRd) vs Daratumumab + VRd (D-VRd): Progression Free Survival (PFS)	103 of 354	50 of 355	709	NCT03710603	Trial comparisons
Velcade Lenalidomide Dexamethasone (VRd) vs Daratumumab + VRd (D-VRd): deaths from any cause	44 of 354	34 of 355	709	NCT03710603	Trial comparisons
Velcade Lenalidomide Dexamethasone (VRd) vs Daratumumab + VRd (D-VRd): Overall MRD Negativity Rate	168 of 354	267 of 355	709	NCT03710603	Trial comparisons
Velcade Lenalidomide Dexamethasone (VRd) vs Daratumumab + VRd (D-VRd): serious adverse events	171 of 347	200 of 351	698	NCT03710603	Trial comparisons

1 to 10 of 202

See all 202 comparisons in its trials

Papers from its trials572

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41038184	RESULT	1	PubMed
39300447	RESULT	1	PubMed
38820500	RESULT	1	PubMed
37753960	RESULT	1	PubMed
37127471	RESULT	1	PubMed
36375046	RESULT	1	PubMed
35660812	RESULT	1	PubMed
35172566	RESULT	1	PubMed
35132679	RESULT	2	PubMed
34779360	RESULT	1	PubMed

1 to 10 of 572

See all 572 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL848

GET https://conductscience.org/api/drugs/v1/CHEMBL848/diseases?page=2

API reference For AI assistants